These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20712135)

  • 1. Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
    Nishikawa T; Matsuzawa Y; Suematsu S; Saito J; Omura M; Kino T
    Arzneimittelforschung; 2010; 60(7):445-51. PubMed ID: 20712135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL).
    Nishikawa T; Suematsu S; Saito J; Soyama A; Ito H; Kino T; Chrousos G
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):309-16. PubMed ID: 15993578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Jones PH
    Am J Cardiol; 2001 Apr; 87(8):1032-4. PubMed ID: 11327075
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.
    Wassmann S; Laufs U; Bäumer AT; Müller K; Konkol C; Sauer H; Böhm M; Nickenig G
    Mol Pharmacol; 2001 Mar; 59(3):646-54. PubMed ID: 11179461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
    Morikawa S; Umetani M; Nakagawa S; Yamazaki H; Suganami H; Inoue K; Kitahara M; Hamakubo T; Kodama T; Saito Y
    J Atheroscler Thromb; 2000; 7(3):138-44. PubMed ID: 11480454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.
    Lu L; Peng WH; Wang W; Wang LJ; Chen QJ; Shen WF
    J Zhejiang Univ Sci B; 2011 Aug; 12(8):652-9. PubMed ID: 21796806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism.
    Zhou S; Zhao P; Li Y; Deng T; Tian L; Li H
    Eur J Pharmacol; 2014 Oct; 740():9-14. PubMed ID: 25008071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
    Wassmann S; Laufs U; Bäumer AT; Müller K; Ahlbory K; Linz W; Itter G; Rösen R; Böhm M; Nickenig G
    Hypertension; 2001 Jun; 37(6):1450-7. PubMed ID: 11408394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG-CoA reductase inhibitors and renal function.
    Campese VM; Park J
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1100-3. PubMed ID: 17942762
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.
    Solini A; Rossi C; Santini E; Madec S; Salvati A; Ferrannini E
    J Hypertens; 2011 Oct; 29(10):1930-9. PubMed ID: 21881526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
    Kolyada AY; Fedtsov A; Madias NE
    Hypertension; 2001 Nov; 38(5):1024-9. PubMed ID: 11711492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
    Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
    Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin inhibits angiotensin II-induced T-type Ca2+ channel expression in endothelial cells.
    Wang D; Hirase T; Inoue T; Node K
    Biochem Biophys Res Commun; 2006 Aug; 347(2):394-400. PubMed ID: 16842760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.
    Telford DE; Edwards JY; Lipson SM; Sutherland B; Barrett PH; Burnett JR; Krul ES; Keller BT; Huff MW
    J Lipid Res; 2003 May; 44(5):943-52. PubMed ID: 12562847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
    Conde K; Roy S; Freake HC; Newton RS; Fernandez ML
    Lipids; 1999 Dec; 34(12):1327-32. PubMed ID: 10652993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin: pharmacological characteristics and lipid-lowering effects.
    Poli A
    Drugs; 2007; 67 Suppl 1():3-15. PubMed ID: 17910517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin attenuates high glucose-induced and angiotensin II-induced MAP kinase activity through inhibition of NAD(P)H oxidase activity in cultured mesangial cells.
    Yu HY; Inoguchi T; Nakayama M; Tsubouchi H; Sato N; Sonoda N; Sasaki S; Kobayashi K; Nawata H
    Med Chem; 2005 Sep; 1(5):461-6. PubMed ID: 16787330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.